Constitutively active mutants of the prolactin receptor
AssigneeInstitut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsVincent Goffin, Philippe Touraine
Life of this patent
Estimating the term…
Abstract
The invention relates to constitutively active mutants of the prolactin receptor (PRLR), wherein an Ile residue at position 76 or at position 146 of the mature form of said receptor has been substituted by another amino acid residue. The invention also provides methods useful for the diagnosis, prognosis, or treatment of diseases involving the PRLR.
Claims9
A method for detecting whether a subject expresses a constitutively active mutant of the prolactin receptor (PRLR) comprising detecting a mutation in the PRLR gene in a nucleic acid sample previously obtained from said subject selected from:
- a mutation resulting in the expression of a constitutively active mutant prolactin receptor, wherein the Ile residue at position 146 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val;
- or
- a mutation resulting in the expression of a constitutively active mutant prolactin receptor wherein the Ile residue at position 76 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val
- wherein the presence of the mutation indicates the presence of the constitutively active mutant.
A method for evaluating whether a woman is prone to develop a breast disease selected from the group consisting of fibroadenoma, multiple fibroadenomas and hypermastia, the method comprising detecting a mutation in the PRLR gene in a nucleic acid sample previously obtained from said subject wherein the mutation is:
- a mutation resulting in the expression of a mutant prolactin receptor, wherein the Ile residue at position 146 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val;
- or
- a mutation resulting in the expression of a mutant prolactin receptor wherein the Ile residue at position 76 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val;
- wherein the presence of the mutation indicates that the woman is prone to develop a breast disease selected from the group consisting of fibroadenoma, multiple fibroadenomas and hypermastia.
A method for assessing the prognosis of a woman presenting with a breast disease selected from the group consisting of fibroadenoma, multiple fibroadenomas and hypermastia, comprising detecting a mutation in the PRLR gene in a nucleic acid sample previously obtained from said subject selected from:
- a mutation resulting in the expression of a mutant prolactin receptor, wherein the Ile residue at position 146 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val;
- or
- a mutation resulting in the expression of a mutant prolactin receptor wherein the Ile residue at position 76 is substituted by another amino acid residue selected from the group consisting of Leu, Met, Thr, Asn, Ser, Phe and Val
- wherein the presence of the mutation indicates the prognosis of the woman.
Dependencies are inferred from the claim text.